EMA Authorised: Ngenla (somatrogon) — Pfizer Europe MA EEIG

View source ↗

Summary

Ngenla (somatrogon) has been authorized by the EMA for growth and development indications in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Disorders
• Growth Hormone Deficiency
• Short Stature Disorders

Drugs mentioned

• NGENLA (SOMATROGON-GHLA)

Snippet

Status: Authorised. Therapeutic area: Growth and Development. MAH: Pfizer Europe MA EEIG. Decision date: 02/07/2026. Orphan medicine